Efficacy and Safety of Ecopipam for Tourette Syndrome: A Meta analysis of Controlled Trials
Objective: To evaluate the efficacy and safety of ecopipam for tic reduction in Tourette syndrome (TS). Background: Ecopipam, a selective dopamine D1 receptor antagonist, has…Dynamics of Motor Fluctuations and Medication Challenges in Parkinson’s Disease
Objective: To investigate the dynamics of tremor, bradykinesia, and finger dexterity during the OFF-to-ON transition using objective measures. Additionally, assesses medication administration challenges through a…Phenytoin Intoxication Masquerading as Generalized Chorea: A Case of Iatrogenic Double-Prescribing
Objective: To report a rare case of phenytoin-induced generalized chorea resulting from inadvertent medication duplication across multiple healthcare facilities, highlighting a preventable cause of acute…Sex Differences in the Reported Prodromal Symptoms of Parkinson’s Disease (PD) in the Fox Insight Cohort
Objective: To identify differences in the self-reported prodromal symptoms of male vs female persons with PD (PwPD) in the Fox Insight (FI) cohort. Background: Early…Suicidal Ideation and the Hippocampal Histaminergic System in Huntington’s Disease: A PET Study
Objective: To determine whether presence and severity of suicidal ideation (SI) are associated with hippocampal volume and histamine H3 receptor (H3R) PET uptake in people with Huntington’s disease (PwHD). Background: Suicidal ideation occurs in approximately 8–27% of PwHD, yet its causes remain unclear(1–3). The…Changes in Continuous Good ON and Best ON Time During the Waking Day With Tavapadon in People With Parkinson’s Disease
Objective: To evaluate motor states throughout the waking day when tavapadon is added to oral carbidopa/levodopa in adults with Parkinson’s disease (PD) experiencing motor fluctuations.…Exploratory Results From a Phase 1 Study of NIO752 in Progressive Supranuclear Palsy Supporting Further Clinical Studies
Objective: To report exploratory analyses of biomarker and clinical outcomes from a first-in-human study of NIO752 in progressive supranuclear palsy (PSP) and provide rationale for…Disassembly of α-Synuclein Aggregates by the All-D-peptide PRI-101: Preclinical Efficacy in Vitro and in Vivo.
Objective: To develop a disease-modifying therapy for Parkinson’s disease (PD) and related synucleinopathies by eliminating intracellular, toxic, and seeding-competent aggregate species of α-synuclein (α-syn). Background:…Neurological disease progression in adults with ataxia telangiectasia – a longitudinal study
Objective: To evaluate longitudinal neurological disease progression in the largest available worldwide cohort of adults with ataxia-telangiectasia. Background: Ataxia-telangiectasia (AT) is a rare, multisystem neurodegenerative…Medication Burden and Associated Challenges for People with Parkinson’s: A Survey of 359 UK Patients
Objective: To quantify medication burden among people with Parkinson’s disease (PD) and explore factors which contribute to medication experience in PD. Background: Individualised, complex medication…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 1942
- Next Page »